NASDAQ:OVID

Ovid Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy OVID

*Your capital is at risk

$2.40

-0.0800 (-3.23%)

At Close: Jun 05, 2026

Currently predicting for Tue, 9 Jun 2026

OVID Live board

Community Bull/Bear

Target Next close

Join the OVID prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

OVID Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For OVID

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

OVID Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT OVID THERAPEUTICS INC

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
RUN $12.83	4.09%	May 06
GLBE $31.61	1.65%	May 05
SAP $172.39	7.18%	May 05
FIZZ $34.11	7.04%	May 01
ADBE $243.57	3.23%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by